TheEdgeResearch
Home / Stocks / SDMHF

Sartorius Stedim Biotech S.A. (SDMHF)

OTC Healthcare Medical - Specialties
$207.50 ▲ +2.72%
Market Cap
$20.19B
Sector
Healthcare
Industry
Medical - Specialties
Beta
1.15
52-Wk Range
178.3-264.3
CEO
René Fáber
Country
FR
Currency
USD

Sartorius Stedim Biotech S.A. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Aubagne, PAC, FR. The stock last traded at $207.50, up 2.72% on the session, giving a market capitalisation of $20.19B. On trailing twelve-month figures it carries a trailing P/E of 59.70, a net margin of 9.7%. Its beta of 1.15 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
59.70
Price / Sales
5.84
Price / Book
4.14
EV / EBITDA
22.27
Gross margin
44.9%
Operating margin
19.4%
Net margin
9.7%
Return on equity
Debt / equity
0.57
Current ratio
1.16
Dividend yield
0.4%
Payout ratio
22.9%
Company profile
Exchange
Other OTC
Employees
10,265
IPO date
2009-08-03
Headquarters
Aubagne, PAC, FR
About Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Comparable companies

Sartorius Stedim Biotech S.A. is most often compared with the following Healthcare names:

CLPBFCLPBYOTSKFSARTFSAUHFSAUHYSSSGYSUVPFTRUMFTRUMY
More research on SDMHF
SDMHF technical analysis SDMHF TheEdge Score Compare against peers
Open full interactive analysis & DCF →